Targeting Genes: A new Strategy in Pancreatic Cancer Treatment

Pancreatic cancer, a notably aggressive form of the disease, is projected to become the second leading cause of cancer-related deaths globally by 2030. However, recent research offers a glimmer of hope. Scientists have identified a potential method to slow the growth of these tumors, marking a crucial initial step in the ongoing battle against this deadly disease.

While the findings, published in Cancer Research, are currently limited to laboratory studies involving mice and cellular aggregates, they represent a significant advancement. The research team, spearheaded by david Tuveson, director of Cold Spring Harbor Laboratory, and featuring Claudia Tonelli, an Italian molecular medicine expert, has termed their work “a race against time.”

Early Detection and existing Drugs: Dual Weapons Against the disease

The path to effectively combating pancreatic cancer remains extensive, but the identification of two key strategies is encouraging. First, the ability to detect the disease at itS earliest stages offers the potential for earlier and more effective intervention. Second, the substance used to slow tumor growth in the laboratory is a drug already approved for clinical use, potentially accelerating the translation of these findings into patient care.

Unveiling the role of FGFR2 in Tumor Aggressiveness

A pivotal aspect of this progress lies in the finding of a cancer-promoting gene, or oncogene, previously known to be involved in other cancer types. According to Tonelli, over 95% of pancreatic tumors exhibit mutations in the Kras gene, a known driver of the disease. The new research reveals that another gene, FGFR2, amplifies the effects of Kras, leading to more aggressive tumor growth.

Over 95% of pancreatic tumors have mutations in the Kras gene… now I discovered that another gene, called FGFR2, plays a role in amplifying the action of the Kras gene. When this happens, the pancreatic cancer becomes more aggressive.
Claudia Tonelli, Cancer Research

Organoids and Mouse Models: Simulating the Disease for Effective Research

These findings stem from experiments conducted on mice and pancreatic organoids, which are three-dimensional tissue models derived from stem cells. The Tuveson-led center has been at the forefront of developing these tumor models, providing invaluable platforms for studying the disease and testing potential therapies. Their pioneering work, dating back a decade, includes the creation of the first pancreatic organoids and mouse models, enabling in-depth investigations of the disease.

Repurposing Existing Drugs: A Promising Therapeutic Avenue

The researchers extended their inquiry beyond simply observing the behavior of the FGFR2 gene.Recognizing its involvement in other cancers, where drugs targeting its activity already exist, they explored the potential of these drugs in treating pancreatic cancer. Some of these drugs are already in clinical use, while others are nearing approval.

Combination Therapy: Blocking Tumor Growth with Multiple Inhibitors

Tonelli and her colleagues tested one of these FGFR2-targeting drugs on both animal models and pancreatic cancer organoids. By carefully monitoring the drug’s effects, they identified the optimal timing for its administration to effectively slow tumor formation. even more promising results were observed when combining the FGFR2 inhibitors with drugs targeting the EGFR protein, which is often overactive in pancreatic cancer. This combination therapy led to the blocking of the disease in numerous models.

This approach aligns with current trends in cancer treatment, which increasingly focus on combination therapies to overcome resistance and improve outcomes. for example, in breast cancer, combining hormone therapy with targeted agents has significantly improved survival rates for certain subtypes.

Future Directions: Clinical Trials and Personalized Medicine

According to Tonelli, With an increasing number of FGFR2 inhibitors entering the clinic, our study lays the base to explore their use in combination with EGFR inhibitors to intercept pancreatic cancer. This research paves the way for future clinical trials to evaluate the efficacy of these combination therapies in patients with pancreatic cancer. Individuals with a family history of the disease are likely to be among the first candidates for such studies.

With an increasing number of FGFR2 inhibitors entering the clinic, our study lays the base to explore their use in combination with EGFR inhibitors to intercept pancreatic cancer.
Claudia Tonelli, cancer Research

This research underscores the importance of personalized medicine in cancer treatment, where therapies are tailored to the specific genetic characteristics of each patient’s tumor.By identifying and targeting key genes like FGFR2, researchers are moving closer to developing more effective and targeted treatments for pancreatic cancer.